Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options - PubMed (original) (raw)
Review
doi: 10.1210/er.2004-0028. Epub 2005 Apr 6.
Affiliations
- PMID: 15814847
- DOI: 10.1210/er.2004-0028
Review
Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options
Satish K Srivastava et al. Endocr Rev. 2005 May.
Abstract
Aldose reductase (AR) is widely expressed aldehyde-metabolizing enzyme. The reduction of glucose by the AR-catalyzed polyol pathway has been linked to the development of secondary diabetic complications. Although treatment with AR inhibitors has been shown to prevent tissue injury in animal models of diabetes, the clinical efficacy of these drugs remains to be established. Recent studies suggest that glucose may be an incidental substrate of AR, which appears to be more adept in catalyzing the reduction of a wide range of aldehydes generated from lipid peroxidation. Moreover, inhibition of the enzyme has been shown to increase inflammation-induced vascular oxidative stress and prevent myocardial protection associated with the late phase of ischemic preconditioning. On the basis of these studies, several investigators have ascribed an important antioxidant role to the enzyme. Additionally, ongoing work indicates that AR is a critical component of intracellular signaling, and inhibition of the enzyme prevents high glucose-, cytokine-, or growth factor-induced activation of protein kinase C and nuclear factor-kappa-binding protein. Thus, treatment with AR inhibitors prevents vascular smooth muscle cell growth and endothelial cell apoptosis in culture and inflammation and restenosis in vivo. Additional studies indicate that the antioxidant and signaling roles of AR are interlinked and that AR regulates protein kinase C and nuclear factor-kappaB via redox-sensitive mechanisms. These data underscore the need for reevaluating anti-AR interventions for the treatment of diabetic complications. Potentially, the development of newer drugs that selectively inhibit AR-mediated glucose metabolism and signaling, without affecting aldehyde detoxification, may be useful in preventing inflammation associated with the development of diabetic complications, particularly micro- and macrovascular diseases.
Similar articles
- Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells.
Ramana KV, Friedrich B, Bhatnagar A, Srivastava SK. Ramana KV, et al. FASEB J. 2003 Feb;17(2):315-7. doi: 10.1096/fj.02-0568fje. Epub 2002 Dec 17. FASEB J. 2003. PMID: 12490536 - Aldose reductase prevents aldehyde toxicity in cultured human lens epithelial cells.
Pladzyk A, Ramana KV, Ansari NH, Srivastava SK. Pladzyk A, et al. Exp Eye Res. 2006 Aug;83(2):408-16. doi: 10.1016/j.exer.2006.01.019. Epub 2006 Apr 24. Exp Eye Res. 2006. PMID: 16631166 - Inhibition of aldose reductase prevents lipopolysaccharide-induced inflammatory response in human lens epithelial cells.
Pladzyk A, Reddy AB, Yadav UC, Tammali R, Ramana KV, Srivastava SK. Pladzyk A, et al. Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5395-403. doi: 10.1167/iovs.06-0469. Invest Ophthalmol Vis Sci. 2006. PMID: 17122129 - Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
Huang Q, Liu Q, Ouyang D. Huang Q, et al. Med Chem. 2019;15(1):3-7. doi: 10.2174/1573406414666180524082445. Med Chem. 2019. PMID: 29792152 Review. - From a dull enzyme to something else: facts and perspectives regarding aldose reductase.
Del Corso A, Cappiello M, Mura U. Del Corso A, et al. Curr Med Chem. 2008;15(15):1452-61. doi: 10.2174/092986708784638870. Curr Med Chem. 2008. PMID: 18537622 Review.
Cited by
- A lipidomic study on the lens epithelial cells of patients with age related cataracts.
Gong Y, Wei Q, Luo L, Qiu W, Jiang Y. Gong Y, et al. PeerJ. 2024 Sep 6;12:e17998. doi: 10.7717/peerj.17998. eCollection 2024. PeerJ. 2024. PMID: 39253600 Free PMC article. - Biomaterials Designed to Modulate Reactive Oxygen Species for Enhanced Bone Regeneration in Diabetic Conditions.
Li M, Zhao Z, Yi J. Li M, et al. J Funct Biomater. 2024 Aug 8;15(8):220. doi: 10.3390/jfb15080220. J Funct Biomater. 2024. PMID: 39194658 Free PMC article. Review. - Aldo-keto reductases: Role in cancer development and theranostics.
Nagini S, Kallamadi PR, Tanagala KKK, Reddy GB. Nagini S, et al. Oncol Res. 2024 Jul 17;32(8):1287-1308. doi: 10.32604/or.2024.049918. eCollection 2024. Oncol Res. 2024. PMID: 39055885 Free PMC article. Review. - Aldose Reductase (AR) Mediates and Perivascular Adipose Tissue (PVAT) Modulates Endothelial Dysfunction of Short-Term High-Fat Diet Feeding in Mice.
Conklin DJ, Haberzettl P, MacKinlay KG, Murphy D, Jin L, Yuan F, Srivastava S, Bhatnagar A. Conklin DJ, et al. Metabolites. 2023 Nov 24;13(12):1172. doi: 10.3390/metabo13121172. Metabolites. 2023. PMID: 38132854 Free PMC article. - Exploring potent aldose reductase inhibitors for anti-diabetic (anti-hyperglycemic) therapy: integrating structure-based drug design, and MMGBSA approaches.
Shahab M, Zheng G, Alshabrmi FM, Bourhia M, Wondmie GF, Mohammad Salamatullah A. Shahab M, et al. Front Mol Biosci. 2023 Nov 20;10:1271569. doi: 10.3389/fmolb.2023.1271569. eCollection 2023. Front Mol Biosci. 2023. PMID: 38053577 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials